Careers
Contact Us

Company
Pipeline
Disease States
Science
Investors

Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

Posted March 4, 2019 by CognitionDev

filed under: Nasdaq

In the News

Jun 7, 2019

Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting

Click to view full release

May 21, 2019

Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting

Click to view full release

May 9, 2019

Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

Click to view full release

See All News

© 2019 Axsome Therapeutics, Inc. All rights reserved. 200 Broadway, 3rd Floor, New York, NY 10038 info@axsome.com

This modal has no inner div